EyePoint Pharmaceuticals announced the Company has entered into a formal two-year contract with one of the largest integrated delivery systems in the U.S. to offer DEXYCU® within its network. This agreement opens up new distribution channels for DEXYCU that were previously unavailable in key U.S. regions, including California, Washington, Georgia, Colorado and mid-Atlantic states. EyePoint has also received Preferred Vendor status from the system.
“This newest agreement makes DEXYCU available to the 8.5 million U.S. patients managed by this integrated delivery system,” said Nancy Lurker, President and CEO of EyePoint Pharmaceuticals. “We continue to receive strong reception and increasing adoption of this innovative product from physicians and ambulatory surgical center across the U.S. DEXYCU has the potential to replace the burdensome post-cataract surgery steroid regimen by providing an easy to administer, extended release treatment option with a favorable safety profile.”